Callaway Golf Company News
Cramer's Mad Money Recap 4/26: General Electric, PepsiCo, Coca-Cola
A look at previous declines for the Dow shows today's losses are barely a blip on the radar, says Jim Cramer.
Cramer's Mad Money Recap 4/7: Amazon, Google, Target
The stock market is changing, says Jim Cramer. And investors need to change, too.
Sonos Makes Bank of America List of Small-Cap Stocks
The stocks are screened for quality, cyclical growth factors, profit margins and buy ratings from BofA analysts.
What's on BofA's List of Quality Small-Cap Growth Stocks?
'Russell 2000 Growth now looks historically cheap vs. Russell 2000 Value, and has also seen better recent revisions,' BofA said.
MarketWatch List of Top 2022 Stocks Includes T-Mobile, GM
It also includes Electronic Arts, Ziff Davis, Callaway Golf, Sunrun, Lending Tree, James River and Celsius Holdings.
Callaway Golf, Dave & Buster's Among January Small Caps at Jefferies
Historically, when small-cap stocks have slid in the fourth quarter, they have rebounded the next quarter, Jefferies said.
Callaway Golf Initiated Buy at Bank of America on Fundamentals
Callaway benefits from 'strong market share in the growing golf equipment market' and 'expected stickiness' among new golfers, Bank of America says.
'Mad Money' Lightning Round: Callaway Golf, Shopify, Chewy
Jim Cramer’s bullish on Callaway Golf, Shopify, Fisker and more.
Cramer's 'Mad Money' Recap: Applied Materials, Paychex
It's futile to speculate on what consumers will do when everyone's vaccinated, says Jim Cramer. Investors should stick with stocks that thrive no matter what.
Alphabet, Tilray, Roku: Latest Upgrades and Downgrades
TheStreet's weekly guide to upgrades, downgrades and price-target changes includes Alphabet, BlackBerry, Roku and DraftKings.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.